Art

J-GLOBAL ID：201902267337697019   Reference number：19A1250420

A CASE OF METASTATIC KIDNEY CANCER FOR WHICH THE EFFICACY OF NIVOLUMAB THERAPY WAS MAINTAINED EVEN AFTER THE DEVELOPMENT OF INTERSTITIAL PNEUMONIA

ニボルマブによる間質性肺炎発症後も有効性が維持されている転移性腎癌の一例

Author (8)： TSUTSUMI SHOGO (神奈川県がんセ 泌尿器科) ,  OKUBO YOICHIRO (神奈川県がんセ 病理診断科) ,  TAKIZAWA AKITOSHI (国際親善病院 泌尿器科) ,  YASUI MASATO (神奈川県がんセ 泌尿器科) ,  NOGUCHI GO (神奈川県がんセ 泌尿器科) ,  UMEMOTO SUSUMU (神奈川県がんセ 泌尿器科) ,  KATO TERUFUMI (神奈川県がんセ 呼吸器内科) ,  KISHIDA TAKESHI (神奈川県がんセ 泌尿器科)
Material： 日本泌尿器科学会雑誌(Web)  (Japanese Journal of Urology (Web))
Volume： 110  Issue： 2  Page： 124-128 (WEB ONLY)  Publication year： 2019 
JST Material Number： U1099A  ISSN： 1884-7110  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： human ,...
Semi thesaurus term： *Kidney cancer ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A1250420&from=J-GLOBAL&jstjournalNo=U1099A") }}

JST classification (3)： Urogenital tumors(=neoplasms)  (GM04000S) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Tumors(=neoplasms)of respiratory system  (GI04000G)

Reference (11)：

• 1) 小野薬品工業: オプジーボ適正使用ガイド. 2016.
• 2) Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, Hatabu H, Ott PA, Armand PF and Hodi FS: PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer Res., 22 (24), 6051-6060, 2016.
• 3) McDermott DF, Drake CG, Sznol M, Choueiri TK, Powderly JD, Smith DC, Brahmer JR, Carvajal RD, Hammers HJ, Puzanov I, Hodi FS, Kluger HM, Topalian SL, Pardoll DM, Wigginton JM, Kollia GD, Gupta A, McDonald D, Sankar V, Sosman JA and Atkins MB: Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol., 33 (18), 2013-2020, 2015.
• 4) McKay RR, Martini D, Moreira RB, Hamieh L, Norton C, Mullane SA, Walsh MK, Michaelson D, McDermott DF and VanAllen E: Outcomes of PD-1/PD-L1 responders who discontinue therapy for immune-related adverse events (irAEs): Results of a cohort of patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol., 2017.
• 5) Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, Carbone DP, Pinder-Schenck MC, Topalian SL, Hodi FS, Sosman JA, Sznol M, McDermott DF, Pardoll DM, Sankar V, Ahlers CM, Salvati M, Wingginton JM, Hellmann MD, Kollia GD, Gupta AK and Brahmer JR: Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol., 3 (18), 2004-2012, 2015.

Terms in the title (4)： ニボルマブ ,  間質性肺炎 ,  発症 ,  転移性腎癌